BioSpecifics Technologies announced that the FDA has accepted for filing and granted priority review of the Biologics License Application (BLA) submitted for Xiaflex. Xiaflex treats Dupuytren’s ...

DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...

The US Food and Drug Administration (FDA) has accepted Auxilium Pharmaceuticals' filing for supplemental Biologics License Application (sBLA) for Xiaflex (collagenase clostridium histolyticum or CCH), ...